Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and ADME of Tazemetostat in B-Cell Lymphomas or Solid Tumors
NCT03010982Phase 1Completed
- Sponsor
- Epizyme, Inc.
- Start
- Jun 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tazemetostat in B cell lymphoma and solid tumor, sponsored by Epizyme, Inc. Primary endpoints: Plasma Pharmacokinetics of [14C] tazemetostat, tazemetostat, and its metabolite EPZ-6930 at Day 15 and Total recovery and relative excretion of radioactivity in urine and feces at Day 16. Started Jun 2018; status: completed.
02
Drugs
tazemetostat
03
Conditions
B cell lymphomasolid tumor
Beyond the preview
Go deeper on NCT03010982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03010982.